Cat. No.: HY-10624

THIQ

Name: THIQ
Brand: MedChemExpress
SKU: HY-10624
Price: 61.00 USD
Availability: InStock
Rating: 5 (1 reviews)

1 Cited Publications

고객리뷰

Based on 1 publication(s) in Google Scholar

THIQ is the first selective agonist of the melanocortin-4 receptor (MC4R), with high affinity and potency for hMC4R (IC₅₀=1.2 nM, EC₅₀=2.1 nM) and rMC4R (IC₅₀=0.6 nM, EC₅₀=2.9 nM). THIQ maintains low potency at MC1R, MC3R and MC5R. THIQ plays a role in eliciting erectile activity in rodents. THIQ acts as a pharmacoperone of the MC4R rescuing the cell surface expression and signaling of some intracellularly retained MC4R mutants.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 98.48%
CAS No.: 312637-48-2
화학식: C₃₃H₄₁ClN₆O₂
분자량:589.17

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

THIQ Chemical Structure

CAS No.: 312637-48-2

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Publications Citing Use of MedChemExpress (MCE) THIQ

Pathol Res Pract. 2022 Jan:229:153717. [Abstract]

Customer Validation & Images

Cell Proliferation/Viability Assay

Cell Proliferation/Viability Assay

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

MC4R

All Melanocortin Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BTI-TN-5B1-4	IC₅₀	9 nM Compound: 1	Binding activity was measured using membranes of Hi5 cells expressing the human MC4R receptors Binding activity was measured using membranes of Hi5 cells expressing the human MC4R receptors	[PMID: 14643322]
CHO	IC₅₀	0.6 nM Compound: 1	Evaluated for binding affinity against rat Melanocortin-4 receptor (rMC4R) by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells Evaluated for binding affinity against rat Melanocortin-4 receptor (rMC4R) by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells	[PMID: 12361385]
CHO	IC₅₀	1.2 nM Compound: 1	Evaluated for binding affinity against human Melanocortin-4 receptor (hMC4R) by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells Evaluated for binding affinity against human Melanocortin-4 receptor (hMC4R) by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells	[PMID: 12361385]
CHO	IC₅₀	1.2 nM Compound: 1	Evaluated for binding affinity against Melanocortin-4 receptor by displacing [125I]-NDP-alpha-MSH radioligand expressed in CHO cells Evaluated for binding affinity against Melanocortin-4 receptor by displacing [125I]-NDP-alpha-MSH radioligand expressed in CHO cells	[PMID: 12361385]
CHO	IC₅₀	1575 nM Compound: 1	Evaluated for binding affinity against rat Melanocortin-5 receptor (rMC5R) by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells Evaluated for binding affinity against rat Melanocortin-5 receptor (rMC5R) by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells	[PMID: 12361385]
CHO	IC₅₀	1883 nM Compound: 1	Evaluated for binding affinity against rat Melanocortin-3 receptor (rMC3R) by displacing [125I]-NDP-alpha-MSH radioligand expressed in CHO cells Evaluated for binding affinity against rat Melanocortin-3 receptor (rMC3R) by displacing [125I]-NDP-alpha-MSH radioligand expressed in CHO cells	[PMID: 12361385]
CHO	IC₅₀	2067 nM Compound: 1	Evaluated for binding affinity against human melanocortin 1 (hMC1R) receptor by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells Evaluated for binding affinity against human melanocortin 1 (hMC1R) receptor by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells	[PMID: 12361385]
CHO	IC₅₀	326 nM Compound: 1	Evaluated for binding affinity against human melanocortin 5 (hMC5R) receptor by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells Evaluated for binding affinity against human melanocortin 5 (hMC5R) receptor by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells	[PMID: 12361385]
CHO	IC₅₀	761 nM Compound: 1	Evaluated for binding affinity against human Melanocortin-3 receptor (hMC3R) by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells Evaluated for binding affinity against human Melanocortin-3 receptor (hMC3R) by displacing [125I]NDP-alpha-MSH radioligand expressed in CHO cells	[PMID: 12361385]
CHO	EC₅₀	5.7 nM Compound: 1	Effective concentration against cAMP release in CHO cells expressing human melanocortin-4 receptor Effective concentration against cAMP release in CHO cells expressing human melanocortin-4 receptor	[PMID: 15357964]
CHO	IC₅₀	1.2 nM Compound: 1	Concentration required for 50% inhibition by displacement of of [125I]NDP-alpha-MSH of human MC4R expressed in CHO cells Concentration required for 50% inhibition by displacement of of [125I]NDP-alpha-MSH of human MC4R expressed in CHO cells	[PMID: 15951175]
CHO	IC₅₀	2063 nM Compound: 1	Concentration required for 50% inhibition by displacement of of [125I]NDP-alpha-MSH of human MC1R expressed in CHO cells Concentration required for 50% inhibition by displacement of of [125I]NDP-alpha-MSH of human MC1R expressed in CHO cells	[PMID: 15951175]
CHO	IC₅₀	326 nM Compound: 1	Concentration required for 50% inhibition by displacement of of [125I]NDP-alpha-MSH of human MC5R expressed in CHO cells Concentration required for 50% inhibition by displacement of of [125I]NDP-alpha-MSH of human MC5R expressed in CHO cells	[PMID: 15951175]
CHO	IC₅₀	761 nM Compound: 1	Concentration required for 50% inhibition by displacement of of [125I]NDP-alpha-MSH of human MC3R expressed in CHO cells Concentration required for 50% inhibition by displacement of of [125I]NDP-alpha-MSH of human MC3R expressed in CHO cells	[PMID: 15951175]
CHO	IC₅₀	1.2 nM Compound: 3	Displacement of [125I]NDP-alpha-MSH from human MC4R expressed in CHO cells Displacement of [125I]NDP-alpha-MSH from human MC4R expressed in CHO cells	[PMID: 16364639]
CHO	IC₅₀	2063 nM Compound: 3	Displacement of [125I]NDP-alpha-MSH from human MC1BR expressed in CHO cells Displacement of [125I]NDP-alpha-MSH from human MC1BR expressed in CHO cells	[PMID: 16364639]
CHO	IC₅₀	326 nM Compound: 3	Displacement of [125I]NDP-alpha-MSH from human MC5R expressed in CHO cells Displacement of [125I]NDP-alpha-MSH from human MC5R expressed in CHO cells	[PMID: 16364639]
CHO	IC₅₀	761 nM Compound: 3	Displacement of [125I]NDP-alpha-MSH from human MC3R expressed in CHO cells Displacement of [125I]NDP-alpha-MSH from human MC3R expressed in CHO cells	[PMID: 16364639]
HEK293	EC₅₀	1400 nM Compound: 27	In vitro cAMP accumulation in HEK cells transfected with human Melanocortin 1 receptor (hMC1R) In vitro cAMP accumulation in HEK cells transfected with human Melanocortin 1 receptor (hMC1R)	[PMID: 14552781]
HEK293	EC₅₀	1400 nM Compound: 27	In vitro cAMP accumulation in HEK cells transfected with human Melanocortin 3 receptor (hMC3R) In vitro cAMP accumulation in HEK cells transfected with human Melanocortin 3 receptor (hMC3R)	[PMID: 14552781]
HEK293	EC₅₀	2700 nM Compound: 27	In vitro cAMP accumulation in HEK cells transfected with human Melanocortin 5 receptor (hMC5R) In vitro cAMP accumulation in HEK cells transfected with human Melanocortin 5 receptor (hMC5R)	[PMID: 14552781]
HEK293	EC₅₀	4 nM Compound: 27	Agonistic activity measured as inhibition of cAMP accumulation in HEK cells expressing human Melanocortin 4 receptor (hMC4R) Agonistic activity measured as inhibition of cAMP accumulation in HEK cells expressing human Melanocortin 4 receptor (hMC4R)	[PMID: 14552781]
HEK293	EC₅₀	3.6 nM Compound: 1	Stimulation of adenylate cyclase in HEK293 cells expressing the human MC4R receptor was determined by measuring cAMP accumulation using the RPA559 SPA assay Stimulation of adenylate cyclase in HEK293 cells expressing the human MC4R receptor was determined by measuring cAMP accumulation using the RPA559 SPA assay	[PMID: 14643322]
HEK293	EC₅₀	1.45 nM Compound: 4	Agonist activity at human MC4 receptor expressed in HEK293 cells assessed as stimulation of cAMP production Agonist activity at human MC4 receptor expressed in HEK293 cells assessed as stimulation of cAMP production	[PMID: 15615531]
HEK293	EC₅₀	49 nM Compound: 4	Agonist activity at human MC4 D122A mutant expressed in HEK293 cells assessed as stimulation of cAMP production Agonist activity at human MC4 D122A mutant expressed in HEK293 cells assessed as stimulation of cAMP production	[PMID: 15615531]
HEK293	IC₅₀	1.2 nM Compound: 4	Displacement of [125]NDP-MSH from human MC4 receptor expressed in HEK293 cells Displacement of [125]NDP-MSH from human MC4 receptor expressed in HEK293 cells	[PMID: 15615531]
HEK293	EC₅₀	0.61 nM Compound: 3	Agonist activity at the mutant MC4R Y287F expressed in HEK293 cells by cAMP accumulation Agonist activity at the mutant MC4R Y287F expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	0.71 nM Compound: 3	Agonist activity at the mutant MC4R F184A expressed in HEK293 cells by cAMP accumulation Agonist activity at the mutant MC4R F184A expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	0.82 nM Compound: 3	Agonist activity at the mutant MC4R Y268A expressed in HEK293 cells by cAMP accumulation Agonist activity at the mutant MC4R Y268A expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	1.2 nM Compound: 3	Agonist activity at the human wild type MC4R expressed in HEK293 cells by cAMP accumulation Agonist activity at the human wild type MC4R expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	1.5 nM Compound: 3	Agonist activity at the mutant MC4R Y268F expressed in HEK293 cells by cAMP accumulation Agonist activity at the mutant MC4R Y268F expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	12 nM Compound: 3	Agonist activity at the mutant MC4R I125A expressed in HEK293 cells by cAMP accumulation Agonist activity at the mutant MC4R I125A expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	26 nM Compound: 3	Agonist activity at the mutant MC4R Y287A expressed in HEK293 cells by cAMP accumulation Agonist activity at the mutant MC4R Y287A expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	41 nM Compound: 3	Agonist activity at the mutant MC4R I129A expressed in HEK293 cells by cAMP accumulation Agonist activity at the mutant MC4R I129A expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	8.5 nM Compound: 3	Agonist activity at the mutant MC4R F184L expressed in HEK293 cells by cAMP accumulation Agonist activity at the mutant MC4R F184L expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	>1000 nM Compound: 3	Agonist activity at the mutant MC4R I291A expressed in HEK293 cells by cAMP accumulation Agonist activity at the mutant MC4R I291A expressed in HEK293 cells by cAMP accumulation	[PMID: 16451057]
HEK293	EC₅₀	0.001 μM Compound: A	Agonist activity at human MC4 receptor expressed in HEK293 cells Agonist activity at human MC4 receptor expressed in HEK293 cells	[PMID: 18078748]
HEK293	EC₅₀	0.005 μM Compound: A	Agonist activity at human MC1 receptor expressed in HEK293 cells Agonist activity at human MC1 receptor expressed in HEK293 cells	[PMID: 18078748]
HEK293	EC₅₀	0.16 μM Compound: A	Agonist activity at human MC3 receptor expressed in HEK293 cells Agonist activity at human MC3 receptor expressed in HEK293 cells	[PMID: 18078748]

In Vitro

THIQ maintains low potency at human MC1R, MC3R and MC5R with IC₅₀s of 2067, 761, 326 nM and EC₅₀s of 2850, 2487, 737 nM, resepectively. THIQ maintains low potency at rat MC3R and MC5R with IC₅₀s 1883 and 1575 nM, and EC₅₀s of 1325 and >3000 nM, respectively^[1].
? THIQ (10 μM; 24 hours) decreases the signal intensity of WT MC4R by approximately 50% whereas increases that of three mutants (N62S, C84R, and C271Y) in HEK293 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

THIQ (0.3-10 mg/kg; i.v.) dose-dependently increases erections (ED₅₀=0.87 mg/kg) in sexually mature male Sprague Dawley rats. The maximal increase in the number of erections (60%) is detected at 5 mg/kg but was not significantly different from that produced by 1 mg/kg. THIQ (20 mg/kg; p.o.) also produces statistically significant increases in erectile responses with a mean increase of 31±4%^[1].
? THIQ treatment shows the t_1/2 is 0.6 hours in Sprague-Dawley rats (1 mg/kg, i.v. and 10 mg/kg, p.o.)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 312637-48-2
Appearance Solid
분자량 589.17
화학식 C₃₃H₄₁ClN₆O₂
Color White to off-white
SMILES

ClC1=CC=C(C=C1)C[C@@H](NC([C@@H]2NCC3=CC=CC=C3C2)=O)C(N4CCC(C5CCCCC5)(CN6C=NC=N6)CC4)=O
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All Cell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Pathol Res Pract

Identification of AGT and CD44 in methotrexate-resistant colorectal cancer and reversal of methotrexate-resistance. [Abstract]

2022 Jan:229:153717. PMID: 34952427

THIQ purchased from MedChemExpress. Usage Cited in: Pathol Res Pract. 2022 Jan:229:153717. [Abstract]

THIQ (1 mM). The viability of MTX-resistant HT29 and Caco2 cells following various treatments was assessed using the CCK-8 assay.

용액&용해도

In Vitro:

DMSO : 100 mg/mL (169.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6973 mL

8.4865 mL

16.9730 mL

5 mM

0.3395 mL

1.6973 mL

3.3946 mL

10 mM

0.1697 mL

0.8487 mL

1.6973 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sebhat IK, et al. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem. 2002 Oct 10;45(21):4589-93. [Content Brief]

[2]. Huang H, et al. A small molecule agonist THIQ as a novel pharmacoperone for intracellularly retainedmelanocortin-4 receptor mutants. Int J Biol Sci. 2014 Jul 20;10(8):817-24. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6973 mL	8.4865 mL	16.9730 mL	42.4326 mL
	5 mM	0.3395 mL	1.6973 mL	3.3946 mL	8.4865 mL
	10 mM	0.1697 mL	0.8487 mL	1.6973 mL	4.2433 mL
	15 mM	0.1132 mL	0.5658 mL	1.1315 mL	2.8288 mL
	20 mM	0.0849 mL	0.4243 mL	0.8487 mL	2.1216 mL
	25 mM	0.0679 mL	0.3395 mL	0.6789 mL	1.6973 mL
	30 mM	0.0566 mL	0.2829 mL	0.5658 mL	1.4144 mL
	40 mM	0.0424 mL	0.2122 mL	0.4243 mL	1.0608 mL
	50 mM	0.0339 mL	0.1697 mL	0.3395 mL	0.8487 mL
	60 mM	0.0283 mL	0.1414 mL	0.2829 mL	0.7072 mL
	80 mM	0.0212 mL	0.1061 mL	0.2122 mL	0.5304 mL
	100 mM	0.0170 mL	0.0849 mL	0.1697 mL	0.4243 mL

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

THIQ

Publications Citing Use of MedChemExpress (MCE) THIQ

All Melanocortin Receptor Isoforms